The VAMP program intends to use lessons learned from COVID-19 vaccine efforts to shorten future emergency response timelines and develop interim capabilities, approved or authorized by the U.S. Food and Drug Administration (FDA).
A request for prototype proposal (RPP) will support will support the Vaccine Acceleration by Modular Progression (VAMP) program through December 13, 2021. These offers will include mRNA vaccine design, non-clinical testing, and clinical testing against priority biological threats.
The effort is led by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense’s (JPEO-CBRND) Joint Project Manager for CBRN Medical (JPM CBRN Medical), in collaboration with the JPEO-CBRND’s Joint Project Lead for CBRN Defense Enabling Biotechnologies (JPL CBRND EB), and the U.S. Department of Health and Human Services’ (HHS) Biomedical Advanced Research and Development Authority (BARDA),
In July 2021, the JPM CBRN Medical held an mRNA vaccine development and delivery industry day to gauge interest in new vaccine technologies from academia, industry, and nonprofits. The RPP is a result of the discussions held with these CBRN defense stakeholders.
The success of the COVID-19 vaccines have shown us that investment in mRNA vaccine technology holds great promise to enable development of a framework and potentially strategic reserves to cover broader threat families, faster.Col. Ryan Eckmeier, the Joint Project Manager for CBRN Medical
To join the solicitation, or read the full text of the solicitation, interested companies need to be members of the Medical CBRN Defense Consortium (MCDC). Visit the MCDC website to learn more about the consortium, how to join the consortium, and how to participate in the RPP.